DCAS | Jotup

DCAS Accepting Non-Dealer Committee Membership Applications for 2024

Retrieved on:

Friday, March 15, 2024

Consulting, Banking, Professional Services, Finance, Letter, ISDA, Committee, DCAS

DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a Non-dealer Committee Member of the Determinations Committee for the relevant region.

Key Points:

DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a Non-dealer Committee Member of the Determinations Committee for the relevant region.
Parties wishing to apply for such a position should carefully review and submit an executed Non-dealer Committee Participation Letter by 5pm (New York time) on Wednesday, March 20, 2024.
For more information on the process and to download the form of the Non-dealer Committee Participation Letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-committees/constitu... .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315301830/en/

Response Plus Medical announces strategic acquisition of UK-based Prometheus as part of global expansion plans

Retrieved on:

Monday, January 22, 2024

Prometheus is part of Safeguard Medical, a global provider of innovative emergency medical technologies and specialized training for first responders.

Key Points:

Prometheus is part of Safeguard Medical, a global provider of innovative emergency medical technologies and specialized training for first responders.
RPM is part of Response Plus Holding PJSC, the largest pre-hospital medical services provider in the UAE and KSA, listed on the Abu Dhabi Securities Exchange.
This acquisition brings together two leading healthcare providers forming a credible Global healthcare platform for Energy and Defense companies.
Dr. Rohil Raghavan, CEO of Response Plus Medical, reinforced the importance of this acquisition in implementing the company's global expansion strategy.

Epic Bio to Present at the Upcoming CRISPR2.0 Conference

Retrieved on:

Tuesday, November 21, 2023

DCAS, Gene expression, Biotechnology, SAN

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.

Key Points:

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.
Learn more about CRISPR2.0 and register to participate here: https://crispr-conference.com/

FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Retrieved on:

Thursday, November 16, 2023

Safety, SAN, Food, Disease, Biotechnology, FSHD, Patient, FDA, Gene expression, DCAS, Trial of the century, Muscular dystrophy, Facioscapulohumeral muscular dystrophy, DUX4, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. EPI-321 is an investigational therapy being developed as a potential single-dose treatment to suppress abnormal expression of the DUX4 gene.

Key Points:

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults.
EPI-321 is an investigational therapy being developed as a potential single-dose treatment to suppress abnormal expression of the DUX4 gene.
Epic plans to initiate a first-in-human, Phase 1/2 clinical study of EPI-321 in the first half of 2024.
The multi-center study will be designed to assess the safety, activity, and preliminary efficacy of EPI-321 in individuals with FSHD.

Approved Oil Company Secures Exclusive Multi-Year Deal to Power All NYC Agencies with Renewable Diesel, Boosting Green Initiatives Citywide

Retrieved on:

Friday, December 1, 2023

In a historic move, Approved Oil Company has emerged as a leader in the distribution of Renewable Diesel within the city's borders.

Key Points:

In a historic move, Approved Oil Company has emerged as a leader in the distribution of Renewable Diesel within the city's borders.
The Department of Citywide Administrative Services (DCAS) has recognized Approved Oil Company's dedication to sustainable solutions and has awarded the company a prestigious multi-year contract.
By powering these essential agency fleets with Renewable Diesel, Approved Oil Company is playing a pivotal role in driving down carbon emissions and contributing to the realization of New York City's ambitious green initiatives.
As a local NYC based company, Approved Oil is particularly proud to have secured this landmark multi-year deal to supply the city with renewable diesel thereby contributing in a major way to supporting NYC's green initiatives.

Epic Bio to Participate in Upcoming Investor Conference

Retrieved on:

Tuesday, November 7, 2023

Biotechnology, Stifel, Gene expression, DCAS, SAN

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the management will participate in an upcoming investor conference:

Key Points:

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the management will participate in an upcoming investor conference:
Corporate presentation: Wednesday, November 15 at 10:20 a.m.
ET
Institutional investors interested in meeting with management during the conference may reach out to their Stifel representative.

Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability

Retrieved on:

Thursday, October 26, 2023

Science, AAV, DCAS, Facioscapulohumeral muscular dystrophy, Biotechnology, FSHD, PAMS, Congress, Dicarboxylic acid, Cell, GEMS, Gene, ESGCT, European Society of Gene and Cell Therapy, Patient, Gene expression, SAN, Vaccine, Cas

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.

Key Points:

These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.
Among the data being presented are new details on Epic’s in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas protein known to work in human cells.
In new data at ESGCT, Epic reports that these three Cas effectors also display greater flexibility in the genetic sequences, called PAMs, that they can target.
“These data highlight why GEMS is an unparalleled therapeutic platform, and how our team’s unique expertise is expanding the state of the science in epigenetic editing every day.”

Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy

Retrieved on:

Thursday, October 19, 2023

Biotechnology, Cell, European Society of Gene and Cell Therapy, Gene expression, DCAS, SAN, ESGCT, Vaccine, Online shopping, Science

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced four poster presentations at the upcoming European Society of Gene and Cell Therapy taking place October 24-27, 2023, in Brussels, Belgium.

Key Points:

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio , a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced four poster presentations at the upcoming European Society of Gene and Cell Therapy taking place October 24-27, 2023, in Brussels, Belgium.
The ESGCT posters will be made available on the Science page of the Epic Bio website following the conference.

New Property Insurance Platform Identifies Indemnity Claims Leakage

Retrieved on:

Tuesday, October 24, 2023

Fintech, Power, DCA, DCAS, Lloyd's of London, Insurance

SPARTANBURG, S.C., Oct. 24, 2023 /PRNewswire/ -- Insurtech, Loss Data Solutions, LLC has developed an automated platform that UK-based syndicates can use to control indemnity claim leakage, a major driver of costs.

Key Points:

SPARTANBURG, S.C., Oct. 24, 2023 /PRNewswire/ -- Insurtech, Loss Data Solutions, LLC has developed an automated platform that UK-based syndicates can use to control indemnity claim leakage, a major driver of costs.
The syndicate focused on managing subrogation, legal spend, and loss-adjusting expenses but not on managing indemnity claim leakage.
This was a problem because indemnity claims leakage – i.e., over- and underestimating property damage – is a significant cost driver.
The automated estimate review increases DCA oversight while reducing DCA expenses associated with a line-by-line review and avoiding potential indemnity leakage.

Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer

Retrieved on:

Tuesday, October 17, 2023

Gene expression, Drug development, Sangamo Therapeutics, Sickle cell disease, Emory University, Louisiana State University, University, DCAS, Biotechnology, SAN, Hematology, Patient, Medical device

Dr. Miller is an accomplished leader in cell and gene therapy drug development whose experience includes development roles at Graphite Bio, Astellas Gene Therapies, and Sangamo Therapeutics.

Key Points:

Dr. Miller is an accomplished leader in cell and gene therapy drug development whose experience includes development roles at Graphite Bio, Astellas Gene Therapies, and Sangamo Therapeutics.
He joins Epic as the company prepares to initiate a first-in-human study of its lead candidate, EPI-321, in early 2024.
“We are excited to welcome Wes, whose extensive experience in clinical practice, drug development and global medical affairs will bolster our leadership team and help shape Epic’s next chapter as a clinical-stage company,” said Amber Salzman, Ph.D., chief executive officer of Epic Bio.
“Epic Bio has built a platform that I believe is unique among the genomic medicine approaches now in development.